Supplementary Figures S1-S12 from Genetic and Pharmacological Screens Converge in Identifying FLIP, BCL2, and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC201/TIC10

Supplementary Figures S1-S12. Validation of kinase regulators of ONC201 sensitivity (S1); KSR1 shifts the ONC201, but not lapatinib, dose-response curve downward (S2); KSR1 does not regulate ONC201-induced TRAIL or DR5 (S3); KSR1 does not affect ONC201-mediated inhibition of MAPK or Akt inhibition (S4); Distribution of ONC201 synergy instances by drug (S5); Validation of ONC201 combinatorial activity with approved anti-cancer small molecules (S6); ONC201 synergizes with sorafenib in HepG2 cells (S7); ONC201 and sorafenib cooperatively induce apoptosis, TRAIL, and DR5 in vivo (S8); ONC201 and sorafenib cooperatively induce apoptosis in HepG2 cells (S9); ONC201 and sorafenib combination therapy is well tolerated and effective in vivo (S10); FLIP, Mcl-1, and KSR-1 knockdown enhances ONC201 response in HCT116 cells (S11); Model of ONC201-induced TRAIL signaling and sensitivity factors (S12).